Summit Therapeutics Inc. - Common Stock (SMMT)

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics (NASDAQ:SMMT) stock rose

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company’s cash position as it prepares for a potential U.S. regulatory decision later this year.

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Biotech companies have always licensed programs, but never so many from one region in particular.

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.

The next 10 months might be challenging for this biotech.

Summit (SMMT) Q4 2025 Earnings Call Transcript

The iShares Ethereum Trust ETF provides regulated exposure to ether’s price performance for institutional and retail investors alike.

SharpLink Gaming connects sports fans and publishers to betting operators through affiliate marketing and data-driven acquisition solutions.

These innovative biotechs could have plenty of upside ahead.

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of

And, if all goes well, over the next five years as well.

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and